The Committee on Drugs (COD) reviews all aspects of pediatric pharmacology including drug indications, contraindications, absorption rates, routes of administration, dosing, use precautions and mode of action as they apply to children. COD also advises the Board of Directors in matters related to drug labeling, safety and efficacy for both prescription and over-the-counter drugs; monitors federal legislation related to the drug approval process and promotes the need for expanded pediatric drug trials.

View policy statements

Committee Members

Bridgette Jones, MD, FAAP
Kansas City, MO

Adam D Adler, MD, FAAP
Houston TX

Jennifer H Foster, MD, FAAP
Houston, TX

Diane E Hindman, MD, FAAP
Mesa, AZ

Matthew M Laughon, MD, FAAP
Chapel Hill, NC

J Routt Reigart, MD, FAAP
Mount Pleasant, SC

Philip A Verhoef, MD, FAAP
Honolulu, HI

Timothy Wilens, MD
Boston, MA

John James Alexander, MD, FAAP
Washington, DC

Kate Woodworth, MD
Atlanta, GA

Perdita Taylor-Zapata, MD
Laurel, MD

Contact COD